Skip to main content
Springer Nature Link
Log in

Prevention of Febrile Neutropenia

  • Chapter
  • First Online:
Febrile Neutropenia

Abstract

As infection in patients with neutropenia is primarily the direct consequence of chemotherapy-induced neutropenia, attempts to prevent febrile neutropenia (FN) episodes during chemotherapy administration requires the evaluation of the risk factors associated with the development of significant neutropenia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Aapro MS, Bohlius J, Cameron DA, et al; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8-32.

    Google Scholar 

  2. Moreau M, Klastersky J, Schwartzbold A, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenian hematological malignancies. Ann Oncol. 2009;20:513-519.

    Google Scholar 

  3. Hansson EK, Friberg LE. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. Cancer Chemother Pharmacol. 2012;69:881-890.

    Google Scholar 

  4. Chen C, Chan A, Yap K. Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. J Oncol Pharm Pract. 2012;19:111-120.

    Google Scholar 

  5. Chang LL, Schneider SM, Chiang SC, Horng CF. Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer. Cancer Nurs. 2013;36:198-205.

    Google Scholar 

  6. Klastersky J, Gombos A, Georgala A, Awada A. Prevention of neutropenia-related events in elderly patients with hematological cancer. Aging Health. 2011;7:829-842.

    Google Scholar 

  7. Bagnasco F, Haupt R, Fontana V, et al. Risk of repeated febrile episodes during chemotherapy induced granulocytopenbia in children with cancer: a prospective center study. J Chemother. 2012;24:155-160.

    Google Scholar 

  8. Schlesinger A, Paul M, Gafter-Gvili A, Rubinovitch B, Leibovici L. Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:97-107.

    Google Scholar 

  9. Klastersky J, Debusscher L, Weerts D, Daneau D. Use of oral antibiotics in protected units environment: clinical effectiveness and role in the emergence of antibiotic-resistant strains. Pathol Biol (Paris). 1974,22:5-12.

    Google Scholar 

  10. Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International Antimicrobial Therapy Project Group. J Infect Dis. 1984;150:372-379.

    Google Scholar 

  11. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979-995.

    Google Scholar 

  12. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effects of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance. Systematic review and meta-analysis. J Antimicrob Chemother. 2007;59:5-22.

    Google Scholar 

  13. Smith T, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-3205.

    Google Scholar 

  14. Klastersky J, Paesmans M, Georgala A, et al. Outpatients oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24:4129-4134.

    Google Scholar 

  15. Sebban C, Dussart S, Fuhrmann C, et al. Oral moxiflacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer. 2008;16:1017-1023.

    Google Scholar 

  16. Laoprasopwattana K, Khwanna T, Suwankeeree P, Sujjanunt T, Tunyapanit W, Chelae S. Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy. Pediatr Infect Dis J. 2013;32:e94-e98.

    Google Scholar 

  17. Bron D. Bone Marrow Transplantation. In: Klastersky J, Schimpff SC, Senn HJ, eds. Supportive Care in Cancer, A Handbook for Oncologists, Second Edition, Revised and Expanded. New York, NY: Marcel Decker; 1999:166-185.

    Google Scholar 

  18. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158-3167.

    Google Scholar 

  19. Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.

    Google Scholar 

  20. Sunhwa K, Baek J, Min H. Effects of prophylactic hematopoietic colony stimulating factors on stem cell transplantations: meta-analysis. Arch Pharm Res. 2012;35:2013-2020.

    Google Scholar 

  21. Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer. 2010;18:529-541.

    Google Scholar 

  22. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-170.

    Google Scholar 

  23. Lalami Y, Paesmans M, Aoun M, et al. A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer. 2004;12:725-730.

    Google Scholar 

  24. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M; OPPS Working Group; ANC Study Group. Risk of febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44:2069-2076.

    Google Scholar 

  25. Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in breast patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylacticgranulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 2006;17:1205-1212.

    Google Scholar 

  26. Klastersky J, Awada A. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: pegylated versus standard myeloid colony stimulating factors. Do we have a choice? Crit Rev Oncol Hematol. 2011;78:17-23.

    Google Scholar 

  27. Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013;3:11.

    Google Scholar 

  28. Ziakas PD, Kourbeti IS. Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide? Clin Transplant. 2012;26:16-22.

    Google Scholar 

  29. Lyman GH, Shayne M. Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol. 2007;19:299-307.

    Google Scholar 

  30. Wingard JR, Elmongy M. Strategies for minimizing neutropenic lever’s complications: prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol. 2009;72:144-154.

    Google Scholar 

  31. Klastersky J, Georgala A, Ameye L, et al. Febrile neutropenia occurring in patients with solid tumors: is the risk of complications affected by the type of chemotherapy? Support Care Cancer. 2010;18(Suppl 3):S101-S102.

    Google Scholar 

  32. Gerlier L, Lamotte M, Awada A, et al. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin’s lymphoma. BMC Cancer. 2010;10:642.

    Google Scholar 

  33. Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:6908-6918.

    Google Scholar 

  34. Hendler D, Shulamith R, Yerulshalmi, et al. Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy. Am J Clin Oncol. 2011;34:619-624.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre des Tumeurs de l’Universite Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium

    Jean A. Klastersky

Authors
  1. Jean A. Klastersky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean A. Klastersky .

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Healthcare

About this chapter

Cite this chapter

Klastersky, J.A. (2014). Prevention of Febrile Neutropenia. In: Febrile Neutropenia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-70-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-70-2_2

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-907673-69-6

  • Online ISBN: 978-1-907673-70-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics